|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Thrombin-activatable fibrinolysis inhibitor (TAFI,Plasma Procarb-oxypeptidase B,Procarboxypeptidase R,Procarboxypep-tidase U)显示文摘 | Bouma BN Marx PF Mosnier LO | 2001 | Thrombosis Res2001，101，： | 1 |
| 2 | Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control:results from the pioneer study显示文摘 | Pfützner A Marx N Lübben G | | Journal of the American College of Cardiology0，，： | 1 |
| 3 | Thrombin-activatable fibrinolysis inhibitor (TAFI) plasma procarboxypeptidase B,pro-carboxypeptidase R,procarboxypeptidase U显示文摘 | MARX PF MOSNIER LO | 2001 | J Thromb Res2001，101，： | 1 |
| 4 | Identifcation of thrombin activatable fibrinolysis inhibior(TAFI) in human platelets显示文摘 | Mosnier LO Buijtennhuijs P Marx PF | 2003 | Blood2003，101，12： | 1 |
| 5 | Thrombin-activatable fibrinolysis inhibitor(TAFI,plasma procarboxypeptidase B,procarboxypeptidase R,procarboxypeptidase U)显示文摘 | Bouma BN Marx PF Mosnier LO | 2001 | Thromb Res2001，101，5： | 1 |
| 6 | Thrombin-activatable fibrinolysis inhibitor (TAFI,Plasma Procarboxypeptidase B,Procarboxypeptidase R,Procarboxypeptidase U)显示文摘 | Bouma BN Marx PF Mosnier LO | 2001 | Thromb Res2001，101，： | 1 |
| 7 | Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein:the PIOSTAT study显示文摘 | Hanefeld M Marx N Pfüitzner A | 2007 | J Am Coll Cardiol2007，49，3： | 1 |
| 8 | Thrombin activatable fibrinolysis inhibitor(TAFI,plasma procarboxypep2tidase B,procarboxypeptidase R,procarboxypeptidase U)显示文摘 | Bouma B N Marx PF Mosnicr LO | 2001 | Thromb Res2001，101，5： | 1 |
| 9 | Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease显示文摘 | Pfützner A Marx N Walcher D | 2008 | Clin Lab2008，54，： | 1 |
| 10 | Thrombin-activatable fibrinolysis inhibitor (TAFI,plasma procarboxypeptidase B,procarboxypeptidase R,procarboxypeptidase U)显示文摘 | Bouma BN Marx PF Mosnier LO | 2001 | Thromb Res2001，101，5： | 1 |
| 11 | Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than prote olytic cleavage 显示文摘 | Marx PF Hackeng TM Dawson PE | 2000 | Biol Chem2000，275，12： | 1 |
| 12 | 显示文摘 | Marx PF | 2004 | Curr Med Chem2004，11，： | 1 |
| 13 | Role of isoleueine residues 182 and 183 in thrombin-aetivatable fibrinolysisinhibitor显示文摘 | Marx PF Havik SR Bouma BN | 2005 | Thromb Haemost2005，3，6： | 1 |
| 14 | Misinterpretation of cup anteversion in total hip arthroplasty using planar radiography显示文摘 | Marx A von Knoch M Pfrtner J | 2006 | Arch Orthop Trauma Surg2006，126，7： | 1 |
| 15 | Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein:the PIOSTAT Study显示文摘 | Hanefeld M Marx N Pfützner A | | 0，，03： | 1 |
| 16 | Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease显示文摘 | Pfützner A Marx N Walcher D | 2008 | Clin Lab2008，54，78： | 1 |
| 17 | Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein:the PIOSTAT Study显示文摘 | Hanefeld M Marx N Pfützner A | | 0，，03： | 1 |
| 18 | Thrombin-activatable fibrinolysis inhibitor ( TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) 显示文摘 | Bouma BN Marx PF Mosnier LO | 2001 | Thrombosis Research2001，101，5： | 1 |
| 19 | Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein:the PIOSTAT Study显示文摘 | Hanefeld M Marx N Pfützner A | 2007 | J Am Coll Cardiol2007，49，3： | 1 |
| 20 | Recent developments in thrombin-activatable fibrinolysis inhibitor research显示文摘 | Marx PF Verkleij CJ Valls Seron M | 2009 | Mini Rey Med Chem2009，9，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员